PhaseBio Pharmaceuticals Inc (PHAS) is a publicly traded company in the Unknown sector. Across all available filings, 21 corporate insiders have executed 113 transactions totaling $15.6M, demonstrating a bullish sentiment with $14.9M in net insider flow. The most recent transaction on May 19, 2023 involved a transaction of 3,750 shares valued at $0.
No significant insider buying has been recorded for PHAS in the recent period.
No significant insider selling has been recorded for PHAS in the recent period.
Based on recent SEC filings, insider sentiment for PHAS is bullish with an Insider Alignment Score of 98/100 and a net flow of $14.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at PhaseBio Pharmaceuticals Inc (PHAS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 21 insiders are actively trading PHAS stock, having executed 113 transactions in the past 90 days. The most active insider is Scott D. Sandell (Executive), who has made 2 transactions totaling $9.0M.
Get notified when executives and directors at PHAS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| May 19, 2023 | J. Hutson Nancy | Executive | Option Exercise | 3,750 | $N/A | $0 | |
| May 19, 2023 | M. Loewy Caroline | Executive | Option Exercise | 3,750 | $N/A | $0 | |
| May 19, 2023 | Sapir Alex | Executive | Option Exercise | 3,750 | $N/A | $0 | |
| May 19, 2023 | Harrigan Edmund | Executive | Option Exercise | 3,750 | $N/A | $0 | |
| May 19, 2023 | D. Humphries William | Executive | Option Exercise | 2,538 | $N/A | $0 | |
| May 19, 2023 | Thorp Clay | Executive | Option Exercise | 3,750 | $N/A | $0 | |
| May 19, 2023 | Broek Richard Van Den | Executive | Award | 3,750 | $N/A | $0 | |
| Oct 25, 2022 | Associates 13 Lp New Enterprise | Executive | Sale | 1,784,109 | $0.15 | $267.6K | |
| May 23, 2022 | Burkhardt Glen | Executive | Sale | 11,248 | $0.79 | $8.9K | |
| May 20, 2022 | P. Sharp John | Executive | Award | 6,026 | $0.68 | $4.1K | |
| May 20, 2022 | Birchall Jonathan | Executive | Award | 20,000 | $0.68 | $13.6K | |
| May 20, 2022 | Hanson Kristopher | Executive | Award | 4,831 | $0.68 | $3.3K | |
| May 20, 2022 | Burkhardt Glen | Executive | Award | 11,248 | $0.68 | $7.6K | |
| May 20, 2022 | P. Mow Jonathan | Executive | Award | 10,918 | $0.68 | $7.4K | |
| May 20, 2022 | Elizabeth Arnold Susan | Executive | Award | 10,917 | $0.68 | $7.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 27 | $15.3M | 94.4% |
Sale(S) | 13 | $361.1K | 2.2% |
Exercise(M) | 24 | $342.1K | 2.1% |
Award(A) | 27 | $204.3K | 1.3% |
Other(J) | 3 | $0 | 0.0% |
Conversion(C) | 19 | $0 | 0.0% |
Insiders at PhaseBio Pharmaceuticals Inc are accumulating shares at an accelerated pace. With 21 insiders making 113 transactions totaling $15.3M in purchases versus $361.1K in sales, the net buying activity of $14.9M signals strong executive confidence. Scott D. Sandell (Executive) leads the buying activity with $9.0M in transactions across all time.